Fibroblast growth factor 23 and uremic vascular calcification: Is it time to escalate from biomarker status to pathogenic agent?

Orson W. Moe, Makoto Kuro-O

Research output: Contribution to journalComment/debate

5 Scopus citations


Although epidemiologic associations have been informative, the elucidation of the role of fibroblast growth factor 23 (FGF23) in chronic kidney disease (CKD) requires testing with robust experimental models. Jimbo et al. used animal and cell-culture models to query whether FGF23 is a direct 'vasculotoxin.' We discuss the interpretation of their findings. At this juncture, much remains unanswered about the significance of FGF23 elevation in CKD.

Original languageEnglish (US)
Pages (from-to)1022-1023
Number of pages2
JournalKidney international
Issue number5
StatePublished - May 2014


ASJC Scopus subject areas

  • Nephrology

Cite this